DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID versus placebo, at three months, from a single intramu ...
Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an investigational vaccine-alternative monoclonal antibody ...
FDA approves FUROSCIX- for use in pediatric patients weighing 43kg or aboveUSPTO issues five patents for FUROSCIX ReadyFlow Autoinjector WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass., Dec. 23, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback